Utilization of health care services in cancer patients with elevated fear of cancer recurrence. Issue 8 (1st June 2018)

• Record Type: Journal Article
• Authors: Champagne, Alexandra; Ivers, Hans; Savard, Josée
• Is Part Of: Psycho-oncology. Volume 27:Issue 8(2018)
• Page Start: 1958
• Page End: 1964
• Publication Date: 2018-06-01
• Subjects: cancer -- complementary and alternative medicine -- fear of cancer recurrence -- health care utilization -- longitudinal study -- oncology -- psychotropic medication usage; Cancer -- Psychological aspects -- Periodicals; Cancer -- Social aspects -- Periodicals; Neoplasms -- psychology -- Periodicals; 616.9940019
• DOI: 10.1002/pon.4748
• Languages: English
• ISSNs: 1057-9249

Abstract

Abstract: Background: Cancer patients commonly report experiencing fear of cancer recurrence (FCR), which may lead to several negative consequences. This study aimed at examining whether clinical levels of FCR are linked to a greater use of health care services. Method: This is a secondary analysis of a longitudinal study of 962 cancer patients on the epidemiology of cancer‐related insomnia. They completed the Fear of Cancer Recurrence Inventory—Short form (FCRI‐SF) and reported information on their consultations (medical, psychosocial, and complementary and alternative medicine [CAM]) and medication usage (anxiolytics/hypnotics and antidepressants) at 6 time points over an 18‐month period. Results: Results indicated that clinical FCR at baseline was associated with greater consultation rates of medical and psychosocial professionals and a greater usage of anxiolytics/hypnotics and antidepressants. No significant association was found between the FCR level and use of CAM services. While consultation rates of medical and CAM professionals and usage of antidepressants generally increased over time, consultation rates of psychosocial professionals and usage of anxiolytics/hypnotics tended to decrease. Conclusions: Cancer patients with clinical levels of FCR are more likely to consult health care providers and to use psychotropic medications, which may translate into significant costs for society and the patients themselves.